Preventing tumor neovascularisation is one of the strategies recently developed to limit the dissemination of cancer cells and apparition of metastases. Although these approaches could improve the existing treatments, a number of unexpected negative effects have been reported, mainly linked to the hypoxic condition and the subsequent induction of the pro-oncogenic hypoxia inducible factor(s) resulting from cancer cells' oxygen starvation. Here, we checked in vivo on colon cancer cells an alternative approach. It is based on treatment with myo-inositol trispyrophosphate (ITPP), a molecule that leads to increased oxygenation of tumors. We provide evidence that ITPP increases the survival of mice in a model of carcinomatosis of human colon cancer cells implanted into the peritoneal cavity. ITPP also reduced the growth of subcutaneous colon cancer cells xenografted in nu/nu mice. In the subcutaneous tumors, ITPP stimulated the expression of the homeobox gene Cdx2 that is crucial for intestinal differentiation and that also has an anti-tumoral function. On this basis, human colon cancer cells were cultured in vitro in hypoxic conditions. Hypoxia was shown to decrease the level of Cdx2 protein, mRNA and the activity of the Cdx2 promoter. This decline was unrelated to the activation of HIF1a and HIF2a by hypoxia. However, it resulted from the activation of a phosphatidylinositol 3-kinases-like mitogen-activated protein kinase pathway, as assessed by the fact that LY294002 and U0126 restored high Cdx2 expression in hypoxia. Corroborating these results, U0126 recapitulated the increase of Cdx2 triggered by ITPP in subcutaneous colon tumor xenografts. The present study provides evidence that a chemical compound that increases oxygen pressure can antagonize the hypoxic setting and reduce the growth of human colon tumors implanted in nu/nu mice.
INTRODUCTION
Hypoxia is an aggravating factor in cancer that stimulates angiogenesis and consequently the intake of nutrients for tumor growth, and that also opens routes for invasive cells to disseminate out of the primary tumor to form metastases. On this basis, chemotherapy with drugs targeting the vascular endothelial growth factor pathway provides some benefit for the patients. However, a number of unexpected limitations have been encountered, in particular related to the fact that inhibiting vessel formation in tumors starves malignant cells from nutrients and oxygen, which subsequently activates the hypoxia response pathway(s) and the pro-oncogenic hypoxia inducible factor-1 (HIF1). 1 We have previously described myo-inositol trispyrophosphate (ITPP), a molecule that increases the release of bound dioxygen from haemoglobin in vitro and improves oxygen tension under hypoxic conditions in vivo.
2 This molecule ameliorates the exercise capacity of transgenic mice with severe heartfailure 3 and inhibits angiogenesis in a chorioallantoid membrane model. 4 Of note, when used on cancer models, ITPP was shown to reduce the growth of xenografted glioma and leads to the eradication of early liver tumors, 4, 5 opening the possibility that increasing the oxygen load could represent a contrasting alternative to antivascular endothelial growth factor therapy in cancer. Colorectal cancer is the third cause of death by cancer and one of the leading types of cancer in which anti-angiogenic therapy is being evaluated. Here, we report beneficial context-dependent effects of ITPP in colon cancer models. We further show that the intestine-specific homeobox gene, Cdx2, which is crucial for homeostasis of the gut epithelium 6 and also exhibits anti-tumor activity, 7, 8 is a downregulated target of hypoxia in colon cancer cells, while being upregulated by ITPP.
RESULTS AND DISCUSSION
To address whether ITPP has any effect on colon tumour growth, we first used the intraperitoneal carcinomatosis model of HT29 cells implanted in the abdominal cavity of athymic nu/nu mice. 9 Two weeks after the injection of 10 7 cells, a series of 10 mice were treated weekly with ITPP at 1.5 or 2 mg/g body weight or saline buffer. As a positive control for drug therapy, one series of mice was treated with Capecitabine at 0.25 mg/g body weight. The mortality was evaluated during 9 weeks of treatment and surviving mice were then euthanized and autopsied. Both doses of ITPP reduced the mortality as compared to NaCl, slightly better than Capecitabine (Figure 1a) . At the end of the treatment two mice survived in the NaCl group, whereas five, five and four mice survived in the groups treated, respectively, with ITPP 1.5 mg/g, ITPP 2 mg/g and Capecitabine 0.25 mg/g. One of the two NaCltreated mice was tumor free, but this ratio rose to 3/4 in Capecitabine-treated mice and even to 4/5 and 5/5 in mice treated with ITPP at 1.5 and 2 mg/g. These data indicate that ITPP antagonizes colon cancer growth in the model of intraperitoneal carcinomatosis.
Next, 2 Â 10 6 HT29 cells were engrafted under the skin of nu/nu mice to follow up the tumor size during 5 weeks in the model of subcutaneous tumors. ITPP was injected weekly from the time of grafting or starting 2 weeks after cell implantation. Oxygen tension was monitored to assess the activity of ITPP. In untreated animals, it was 30 mm Hg in muscles but only 0.2-2 mm Hg in tumors, signalling their hypoxic setting; 2 h after ITPP administration, oxygen tension remained at 30-34 mm Hg in muscles; however, it strongly increased up to 32 mm Hg in the tumors and persisted above 25 mm Hg 2 days after ITPP administration. Together, this confirmed that ITPP increased the oxygen release inside tumors. As shown in Figure 1b , ITPP significantly reduced the growth of the subcutaneous HT29 tumors, leading to a 6 cells per site of injection, 2 sites of injection per mouse, 4 mice per group) treated weekly with ITPP at 2 mg/g of body weight, starting on the day of cells injection, or with NaCl. Left panel: the proportion of Cdx2-immunolabelled cell nuclei was used to classify the samples of each group of eight tumors into low-, moderately-or highly-Cdx2-expressing tumors; immunohistochemistry was performed as described 11 with the monoclonal antibody CDX2-88 (Biogenex, San Ramon, CA, USA). Right panel: quantification by RT-qPCR of the amount of Cdx2 RNA expressed in the subcutaneous tumors of ITPP-treated mice (grey boxes) and control NaCl-treated mice (white boxes). RT-qPCR was performed as described 8 using the Hs00230919_m1 Cdx2 Gene Specific Assay (Applied Biosystems, Carlsbad, CA, USA). *Po0.05.
Stimulating oxygen load reduces colon cancer growth L Derbal-Wolfrom et al Figure 2 . Effect of hypoxia on Cdx2 expression in human colon cancer cell lines. (a) Comparative expression of the Cdx2 mRNA by RT-qPCR in SW480 and Caco2-TC7 cells cultured in normoxic (20% O 2 , white boxes) and hypoxic conditions (3% O 2 , grey boxes), as described. 17 See the legend of Figure 1 for the RT-qPCR protocol. Experiments were performed in triplicate, *Po0.01. (b) Expression of the Cdx2 protein in SW480 and Caco2TC7 cells cultured in normoxic (20% O 2 ) and hypoxic conditions (3% O 2 and 1% O 2 ). Western blots were performed as described 18 with CDX2-88 antibody (Biogenex). (c) Activity of the 9-kb Cdx2 promoter in pCdx2-9Luc-transfected SW480 cells in normoxic (20% O 2 , white boxes) or hypoxic conditions (3% O 2 , grey boxes). Cells were transfected in normoxia for 4 h with the reporter plasmid pCdx2-9Luc together with the plasmids encoding HNF4a and GATA6 to stimulate the basal Cdx2 promoter activity as described, 14 and then transferred to hypoxic conditions (3% O 2 ) for 24 h before measuring luciferase activity. Experiments were performed in triplicate, *Po0.01. (d) Absence of restoration of Cdx2 expression in hypoxia by knockingdown HIF1a and/or HIF2a. SW480 cells were transfected with the indicated siRNA in normoxia for 4 h as described 8 and then placed in hypoxia (3% O 2 ) for 24 h. The mRNA expression of Cdx2 was assessed by RT-qPCR. The siRNAs were the following: siRNA-ctrl (Allstars Negative Control, Ambion, Foster City, CA, USA), siRNA@HIF1a#1 (s6541, Ambion), siRNA@HIF1a#2 (Hs-HIF1 A-6, Qiagen, Gaithersburg, MD, USA), siRNA@HIF2a#1 (s4698, Ambion), and siRNA@HIF2a#2 (s4699, Ambion). Experiments were performed in triplicate. Western blots illustrate the increased expression of HIF1a and HIF2a in hypoxia compared with the normoxia, and the strongly reduced expression of these factors by the respective siRNA. (e) Absence of downregulation of Cdx2 by overexpression of HIF1a. SW480 cells were transfected with the indicated amounts of plasmid pHA-HIF1a (Addgene, Cambridge, MA, USA) and analysed by western blot 48 h later with antibodies against HIF1a (BD Bioscience, Chicago, IL, USA) and Cdx2 (Biogenex). (f ) SW480 cells seeded in hypoxic conditions (3% O 2 ) were transfected with siRNA-ctrl (Allstars Negative Control, Ambion), siRNA@HIF1a#1 (s6541, Ambion) or siRNA@HIF1a#2 (Hs-HIF1A-6, Qiagen), and the relative mRNA expression of three target genes of HIF1a, DDIT4, NDRG1 and SLC2 A3, was quantified by RT-qPCR relative to HMBS as control, using FastStart DNA Master Mix SYBR Green I (Roche Diagnostics, Indianapolis, IN, USA) and the repective commercial primer kits (Qiagen): Hs_DDIT4_1_SG QuantiTect Primer Assay (QT00238588), Hs_NDRG1_1_SG QuantiTect Primer Assay (QT00059990), Hs_SLC2A3_1_SG QuantiTect Primer Assay (QT00047124) and Hs_HMBS_1_SG QuantiTect Primer Assay (QT00014462).
twofold reduction of the tumor volume. These results are in line with those obtained with the intraperitoneal carcinomatosis model. To evaluate the effect of ITPP on other colon cancer cell lines than HT29, SW480 and HCT116 cells were grafted under the skin of nu/nu mice. As for HT29 cells, SW480 tumor growth was reduced by ITPP; however, the drug was much less efficient on HCT116 tumors (Figure 1c) . Interestingly, unlike HT29 and SW480 cells in which the hypoxia-induced factor HIF1a is extremely low in normoxia, HCT116 cells exhibit a significant constitutive expression of HIF1a already in normoxia (Figure 1d) . Thus, ITPP treatment, which increases oxygen tension in tumors, reduces tumor growth, but not in a cell line in which HIF1a is already expressed in normoxia.
Histological examination of HT29 tumors grown for 5 weeks showed a tendency towards more differentiation under ITTP treatment. The intestine-specific homeobox gene Cdx2 is a major regulator of intestinal differentiation 6,10 whose expression is altered in human colorectal cancers. Cdx2 reduction in colon cancer results in accelerated tumor progression and increased tumor cell migration and dissemination. 7, 8 We have previously reported that although Cdx2 is very low in HT29 cells cultured in vitro, these cells are competent for the expression of this homeobox gene, as it can be turned on when they are grafted subcutaneously in nu/nu mice. 11 These studies have emphasized the relevance of cell interactions between cancer cells and subjacent fibroblasts to stimulate Cdx2, 11 an effect invoving extracellular matrix proteins like laminins. 12, 13 However, until now the expression of Cdx2 was not analysed with regard to the oxygenation status. We therefore addressed whether the ITPP treatment has any effect on Cdx2 expression in tumors grafted for 3, 4 and 5 weeks in nu/nu mice. Immunohistochemistry was used to estimate the proportion of cell nuclei expressing the Cdx2 protein and RNA levels were quantified by reverse transcriptionqPCR. The results illustrated in Figure 1e show that ITPP accelerates the rise of Cdx2 expression in xenografted HT29 tumors.
The above results obtained in vivo suggest that Cdx2 expression might be downregulated by hypoxia. We therefore, addressed this issue in cell lines cultured in vitro. For this purpose, SW480 and Caco 2 -TC7 cells, two human colon cancer cell lines that 6 cells per site of injection, two sites of injection per mouse, six mice per group), treated weekly for 5 weeks with U0126 at 25 mmol/g of body weight or with saline as described. 19 Treatment started 2 weeks after cell injection. Each spot corresponds to one tumor. *Po0.05. RT-qPCR was performed as described in the legend of Figure 1 . (Figure 2c ). HIF1a and HIF2a are major transcription factors known to mediate many of the effects of hypoxia. Knockingdown HIF1a or HIF2a or both HIF1a and HIF2a together using specific small interfering RNA did not prevent the decrease of Cdx2 in SW480 cells cultured in hypoxia (Figure 2d) , although the efficacy of the knockdown was assessed by the inhibition of HIF1a or HIF2a production by the respective small interfering RNA in cells cultured in hypoxia (Figure 2d ) and by the resulting inhibition of three known transcriptional targets of the HIF pathway: DDIT4, NDRG1 and SLC2A3 (Figure 2f) . Conversely, when SW480 cells were cultured in normoxia and transfected with increasing amounts of HIF1a-encoding plasmid to saturate the physiological degradation pathway, the resulting overexpression of HIF1a failed to decrease Cdx2 levels ( Figure 3e ). Together, these data indicate that the expression of Cdx2 is a new target of hypoxia in colorectal cancer cells and that its downregulation by hypoxia is HIFindependent.
We used pharmacological drugs to decipher the pathway(s) involved in the hypoxia-induced decrease of Cdx2. SW480 cells were cultured in normoxia for 24 h, then the drugs were added and the cells were placed in hypoxia for 24 h in the continuous presence of drugs. Cdx2 mRNA was quantified by reverse transcription-qPCR. The inhibitors were Wortmanin and LY294002 for pan-phosphatidylinositol 3-kinase pathways, Sorafenib for RAF, U0126 for mitogen-activated protein kinase, Tetrabromobenzotriazole for Casein Kinase II, rapamycin for mTOR, Tricostatin-A for histone deacetylases and irinotecan for topoisomerase-1; we also used Forskolin to activate adenylate cyclase and the antioxidant N-acetyl-L-cysteine against ROS. Figure 3a indicates that LY294002 and U0126 prevented the Cdx2 decrease triggered by hypoxia, whereas all other compounds were without effect. Adding Sorafenib, Irinotecan or N-acetyl-L-cysteine did not improve the effect of LY294002 or U0126 on Cdx2. In addition, combining LY294009 and U0126 had the same effect as each inhibitor independently, suggesting that both target the same pathway.
The effect of LY294009 and U0126 on the hypoxia-induced downregulation of Cdx2 is consistent with the fact that both Akt and Erk are activated in HT29 and SW480 cells placed in hypoxia (Figures 3b and c) . On the basis of these data obtained in cell lines cultured in vitro, we wondered whether the MEK inhibitor U0126 could also recapitulate the effect of ITPP on Cdx2 expression in xenografted tumors. For this purpose, HT29 cells were grafted subcutaneously in nu/nu mice and the mice were treated either with U0126 at 25 mmol/g of body weight or with saline buffer as control. As illustrated in Figure 3d , inhibiting MEK by U0126 in these hypoxic tumors significantly stimulated Cdx2 expression, as shown previously with the ITPP treatment in vivo.
In conclusion, this study provides evidence that a chemical compound that increases tumor oxygen tension improves the hypoxic setting and reduces the growth of human colon tumors implanted in nu/nu mice, except in a cell line where HIF1a is already expressed in normoxia. Although hypoxia has many more effects, we report here for the first time that it downregulates the intestine-specific homeobox gene Cdx2. As this gene exerts an anti-tumor function through multiple molecular mechanisms including the transcriptional stimulation of a Wnt signalling antagonist, Mucdhl 15 and the transcription-independent reduction of NHEJ DNA repair activity, 16 its restoration is expected to participate in the beneficial outcome resulting from ITPP treatment. Thus, restoring normoxia in tumors could be an alternative way to anti-vascular endothelial growth factor therapies that deserves further investigations and evaluation in preclinical models of cancer, in particular in combination with cytotoxic drugs currently used in chemotherapy. 
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